Activity ratios measure how efficiently a company performs day-to-day tasks, such us the collection of receivables and management of inventory.
Paying user area
Try for free
Cytokinetics Inc. pages available for free this week:
- Balance Sheet: Assets
- Balance Sheet: Liabilities and Stockholders’ Equity
- Common Stock Valuation Ratios
- Enterprise Value to EBITDA (EV/EBITDA)
- Present Value of Free Cash Flow to Equity (FCFE)
- Selected Financial Data since 2005
- Operating Profit Margin since 2005
- Current Ratio since 2005
- Debt to Equity since 2005
- Price to Book Value (P/BV) since 2005
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Cytokinetics Inc. for $22.49.
This is a one-time payment. There is no automatic renewal.
We accept:
Short-term Activity Ratios (Summary)
Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).
The financial ratios under review present notable fluctuations over the five-year period ending in 2022. These ratios shed light on the operational efficiency concerning receivables, payables, and working capital management.
- Receivables Turnover
- This ratio exhibited substantial volatility. It began at 14.12 in 2018, decreased sharply to 5.20 in 2019, then rebounded to 12.63 in 2020. A significant decline occurred in 2021, falling to 1.36, followed by an extraordinary surge to 643.46 in 2022. Such extreme variation suggests inconsistencies in the company's ability to collect receivables or possible changes in credit policy or recording.
- Average Receivable Collection Period
- The pattern is inverse to the receivables turnover, as expected. The collection period increased from 26 days in 2018 to 70 days in 2019, then dropped back to 29 days in 2020. Thereafter, the period expanded drastically to 269 days in 2021, before plummeting to 1 day in 2022. This further emphasizes the irregularity in receivables management and implies significant operational changes in the final year.
- Payables Turnover
- The payables turnover moved from 8.37 in 2018 down to 3.29 in 2019, rose again to 6.94 in 2020, and then decreased to approximately 3.3 in both 2021 and 2022. This indicates that the company generally slowed down its payments to suppliers after 2018, maintaining a more extended payment period since 2019.
- Average Payables Payment Period
- The payment period lengthened substantially from 44 days in 2018 to 111 days in 2019, then shortened to 53 days in 2020. Following this, it increased again to 109 days in 2021 and slightly declined to 99 days in 2022. This behavior corresponds with the lower payables turnover ratios during recent years, indicating a trend toward slower payment practices.
- Working Capital Turnover
- This ratio remained relatively stable but low throughout the period, fluctuating slightly between 0.13 and 0.17. The consistency at a low level suggests limited efficiency in generating revenue from working capital investments over the years.
Overall, the data reveals substantial irregularities and abrupt changes particularly in receivables management during 2021 and 2022, contrasted with more gradual but sustained trends toward slower payables payments. Working capital utilization remained consistently low. These observations could imply significant shifts in operating policies or external influences impacting the company's liquidity management practices.
Turnover Ratios
Average No. Days
Receivables Turnover
Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | ||
---|---|---|---|---|---|---|
Selected Financial Data (US$ in thousands) | ||||||
Revenues | ||||||
Accounts receivable | ||||||
Short-term Activity Ratio | ||||||
Receivables turnover1 | ||||||
Benchmarks | ||||||
Receivables Turnover, Competitors2 | ||||||
AbbVie Inc. | ||||||
Amgen Inc. | ||||||
Bristol-Myers Squibb Co. | ||||||
Danaher Corp. | ||||||
Eli Lilly & Co. | ||||||
Gilead Sciences Inc. | ||||||
Johnson & Johnson | ||||||
Merck & Co. Inc. | ||||||
Pfizer Inc. | ||||||
Regeneron Pharmaceuticals Inc. | ||||||
Thermo Fisher Scientific Inc. | ||||||
Vertex Pharmaceuticals Inc. | ||||||
Receivables Turnover, Sector | ||||||
Pharmaceuticals, Biotechnology & Life Sciences | ||||||
Receivables Turnover, Industry | ||||||
Health Care |
Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).
1 2022 Calculation
Receivables turnover = Revenues ÷ Accounts receivable
= ÷ =
2 Click competitor name to see calculations.
- Revenue Trend
- Revenue exhibited a generally increasing trend over the five-year period. Starting at $31,501 thousand in 2018, revenue declined to $26,868 thousand in 2019 but then increased significantly to $55,828 thousand in 2020. This upward trajectory continued in 2021 and 2022, culminating in revenues of $70,428 thousand and $94,588 thousand respectively, representing a substantial growth over the period.
- Accounts Receivable Pattern
- Accounts receivable values showed considerable fluctuation. From $2,231 thousand in 2018, there was an increase to $5,163 thousand in 2019, followed by a slight decline to $4,420 thousand in 2020. A notable spike occurred in 2021, where accounts receivable escalated dramatically to $51,819 thousand before dropping sharply to $147 thousand in 2022. This volatility indicates irregularities or significant changes in credit policies or collection processes.
- Receivables Turnover Analysis
- Receivables turnover demonstrated high variability. It started at a robust 14.12 in 2018, decreased substantially to 5.2 in 2019, then rebounded to 12.63 in 2020. In 2021, the ratio dropped dramatically to 1.36, aligning with the sharp increase in accounts receivable that year. The turnover then surged to an exceptionally high figure of 643.46 in 2022, coinciding with the drastic reduction in receivables. This pattern suggests significant changes in how efficiently accounts receivable are being collected, with 2021 likely representing a period of slower collections and 2022 a year of accelerated collections or write-offs.
- Overall Insights
- The revenue growth trend is positive and consistent after 2019. However, the fluctuations in accounts receivable and the corresponding turnover ratios indicate operational inconsistencies or significant adjustments in credit management practice. The extreme variations in turnover, especially in the last two years, warrant further investigation to understand the underlying causes and ensure sustainable receivables management aligned with revenue growth.
Payables Turnover
Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | ||
---|---|---|---|---|---|---|
Selected Financial Data (US$ in thousands) | ||||||
Revenues | ||||||
Accounts payable | ||||||
Short-term Activity Ratio | ||||||
Payables turnover1 | ||||||
Benchmarks | ||||||
Payables Turnover, Competitors2 | ||||||
AbbVie Inc. | ||||||
Amgen Inc. | ||||||
Bristol-Myers Squibb Co. | ||||||
Danaher Corp. | ||||||
Eli Lilly & Co. | ||||||
Gilead Sciences Inc. | ||||||
Johnson & Johnson | ||||||
Merck & Co. Inc. | ||||||
Pfizer Inc. | ||||||
Regeneron Pharmaceuticals Inc. | ||||||
Thermo Fisher Scientific Inc. | ||||||
Vertex Pharmaceuticals Inc. | ||||||
Payables Turnover, Sector | ||||||
Pharmaceuticals, Biotechnology & Life Sciences | ||||||
Payables Turnover, Industry | ||||||
Health Care |
Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).
1 2022 Calculation
Payables turnover = Revenues ÷ Accounts payable
= ÷ =
2 Click competitor name to see calculations.
- Revenues
- The revenues exhibit an overall upward trend throughout the specified periods. Starting at $31.5 million in 2018, revenues decreased to $26.9 million in 2019. However, from 2019 onwards, there was a significant increase, with revenues reaching $55.8 million in 2020, $70.4 million in 2021, and further rising to $94.6 million in 2022. This shows strong growth momentum post-2019.
- Accounts Payable
- Accounts payable demonstrated considerable volatility and growth over the years. Beginning at approximately $3.8 million in 2018, it more than doubled to $8.2 million in 2019. The figure remained nearly stable at about $8 million in 2020, then sharply increased to $21.1 million in 2021 and further to $25.6 million in 2022. This substantial increase in payables suggests expanded procurement or delayed payment terms aligned with elevated business activity.
- Payables Turnover Ratio
- The payables turnover ratio, which indicates how many times payables are paid over a period, shows significant fluctuations. It decreased sharply from 8.37 in 2018 to 3.29 in 2019, indicating slower payments relative to purchases. The ratio rose again to 6.94 in 2020, suggesting quicker payment cycles that year. However, it fell again in 2021 to 3.34 and slightly increased to 3.69 in 2022, implying a return to longer payment cycles despite growing accounts payable amounts.
- Overall Observations
- The data indicates a period of rapid revenue growth after 2019 accompanied by rising accounts payable balances. The decreasing payables turnover ratio in recent years suggests that the company has extended its payment terms or slowed payment rates despite increasing volume of payables, which could impact supplier relationships or cash management. The growth in revenues evidences strong operational performance, while changes in payables and payment rates point to evolving working capital management strategies.
Working Capital Turnover
Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | ||
---|---|---|---|---|---|---|
Selected Financial Data (US$ in thousands) | ||||||
Current assets | ||||||
Less: Current liabilities | ||||||
Working capital | ||||||
Revenues | ||||||
Short-term Activity Ratio | ||||||
Working capital turnover1 | ||||||
Benchmarks | ||||||
Working Capital Turnover, Competitors2 | ||||||
AbbVie Inc. | ||||||
Amgen Inc. | ||||||
Bristol-Myers Squibb Co. | ||||||
Danaher Corp. | ||||||
Eli Lilly & Co. | ||||||
Gilead Sciences Inc. | ||||||
Johnson & Johnson | ||||||
Merck & Co. Inc. | ||||||
Pfizer Inc. | ||||||
Regeneron Pharmaceuticals Inc. | ||||||
Thermo Fisher Scientific Inc. | ||||||
Vertex Pharmaceuticals Inc. | ||||||
Working Capital Turnover, Sector | ||||||
Pharmaceuticals, Biotechnology & Life Sciences | ||||||
Working Capital Turnover, Industry | ||||||
Health Care |
Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).
1 2022 Calculation
Working capital turnover = Revenues ÷ Working capital
= ÷ =
2 Click competitor name to see calculations.
The financial data reveals several key trends over the five-year period ending December 31, 2022.
- Working Capital
- The working capital demonstrates a consistent upward trajectory across the period. Starting from $185,480 thousand in 2018, it increases annually to reach $710,569 thousand by 2022. This growth suggests an improvement in short-term financial health and liquidity, indicating the company has more resources available to cover its current liabilities over time.
- Revenues
- Revenues exhibit a pattern of volatility but generally a strong upward trend. After a decline from $31,501 thousand in 2018 to $26,868 thousand in 2019, revenues rebounded significantly to $55,828 thousand in 2020 and continued to increase to $94,588 thousand by 2022. This growth may indicate enhanced operational performance, market expansion, or successful product development.
- Working Capital Turnover
- The working capital turnover ratio remains relatively stable but low throughout the period, fluctuating between 0.13 and 0.17. This ratio reflects the efficiency with which the company uses its working capital to generate revenues. Despite the substantial increase in working capital, turnover does not show a corresponding improvement, remaining close to 0.13 in 2022, which could indicate that the increase in working capital is not proportionally translating into increased revenue efficiency.
In summary, the company shows significant growth in working capital and revenues over the five years, indicating an expanding scale of operations and improved liquidity. However, the relatively flat working capital turnover ratio suggests that the efficiency of utilizing working capital to generate sales has not notably improved, which may warrant further efficiency analysis and operational review.
Average Receivable Collection Period
Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | ||
---|---|---|---|---|---|---|
Selected Financial Data | ||||||
Receivables turnover | ||||||
Short-term Activity Ratio (no. days) | ||||||
Average receivable collection period1 | ||||||
Benchmarks (no. days) | ||||||
Average Receivable Collection Period, Competitors2 | ||||||
AbbVie Inc. | ||||||
Amgen Inc. | ||||||
Bristol-Myers Squibb Co. | ||||||
Danaher Corp. | ||||||
Eli Lilly & Co. | ||||||
Gilead Sciences Inc. | ||||||
Johnson & Johnson | ||||||
Merck & Co. Inc. | ||||||
Pfizer Inc. | ||||||
Regeneron Pharmaceuticals Inc. | ||||||
Thermo Fisher Scientific Inc. | ||||||
Vertex Pharmaceuticals Inc. | ||||||
Average Receivable Collection Period, Sector | ||||||
Pharmaceuticals, Biotechnology & Life Sciences | ||||||
Average Receivable Collection Period, Industry | ||||||
Health Care |
Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).
1 2022 Calculation
Average receivable collection period = 365 ÷ Receivables turnover
= 365 ÷ =
2 Click competitor name to see calculations.
- Receivables Turnover
- The receivables turnover ratio demonstrates significant volatility over the observed periods. Initially, the ratio decreased notably from 14.12 in 2018 to 5.2 in 2019, indicating a slower collection pace of accounts receivable. This was followed by a recovery to 12.63 in 2020, suggesting improved efficiency in collections. However, the ratio sharply declined to 1.36 in 2021, reflecting a marked slowdown in receivables turnover. In 2022, the ratio surged unexpectedly to 643.46, an unusually high value that may indicate an exceptional or non-recurring event affecting receivables or revenue recognition.
- Average Receivable Collection Period
- The average receivable collection period exhibited an inverse pattern relative to the receivables turnover ratio. It started at 26 days in 2018 and increased significantly to 70 days in 2019, indicating a longer time to collect receivables. In 2020, this period shortened to 29 days, corresponding with the improved turnover ratio. Contrarily, the collection period extended drastically to 269 days in 2021, consistent with the sharp decline in turnover ratio, thus showing a considerable deterioration in collection efficiency. In 2022, the collection period dropped sharply to 1 day, which aligns with the extraordinary increase in turnover ratio and suggests an exceptional improvement or possible data anomaly.
Average Payables Payment Period
Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | ||
---|---|---|---|---|---|---|
Selected Financial Data | ||||||
Payables turnover | ||||||
Short-term Activity Ratio (no. days) | ||||||
Average payables payment period1 | ||||||
Benchmarks (no. days) | ||||||
Average Payables Payment Period, Competitors2 | ||||||
AbbVie Inc. | ||||||
Amgen Inc. | ||||||
Bristol-Myers Squibb Co. | ||||||
Danaher Corp. | ||||||
Eli Lilly & Co. | ||||||
Gilead Sciences Inc. | ||||||
Johnson & Johnson | ||||||
Merck & Co. Inc. | ||||||
Pfizer Inc. | ||||||
Regeneron Pharmaceuticals Inc. | ||||||
Thermo Fisher Scientific Inc. | ||||||
Vertex Pharmaceuticals Inc. | ||||||
Average Payables Payment Period, Sector | ||||||
Pharmaceuticals, Biotechnology & Life Sciences | ||||||
Average Payables Payment Period, Industry | ||||||
Health Care |
Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).
1 2022 Calculation
Average payables payment period = 365 ÷ Payables turnover
= 365 ÷ =
2 Click competitor name to see calculations.
- Payables Turnover
- The payables turnover ratio exhibits notable fluctuations over the observed period. Starting at a relatively high level of 8.37 in 2018, it experienced a significant decline to 3.29 in 2019. The ratio rebounded to 6.94 in 2020, indicating an improvement in the frequency of payments to suppliers. However, this improvement was short-lived as the ratio decreased again to 3.34 in 2021, and showed a slight increase to 3.69 in 2022. Overall, the payables turnover is characterized by volatility with a general downward trend from the initial value in 2018.
- Average Payables Payment Period
- The average payables payment period show an inverse relationship with the payables turnover, as expected. The period lengthened considerably from 44 days in 2018 to 111 days in 2019, indicating slower payments to suppliers. It then shortened to 53 days in 2020, corresponding with the temporary improvement in payables turnover. Subsequently, the payment period extended again, reaching 109 days in 2021 and somewhat decreasing but remaining elevated at 99 days in 2022. This pattern suggests a tendency towards longer payment terms in recent years, which may impact supplier relationships and cash flow management.